Increased fibrillar amyloid-β burden in normal individuals with a family history of late-onset Alzheimer's

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 13, 2010, Pages 5949-5954

  Mosconi, Lisa ^a   Rinne, Juha O ^b   Tsui, Wai H ^a,c   Berti, Valentina ^a,d   Li, Yi ^a   Wang, Huiyu ^a   Murray, John ^a   Scheinin, Noora ^b   Någren, Kjell ^b,e   Williams, Schantel ^a   Glodzik, Lidia ^a   De Santi, Susan ^a   Vallabhajosula, Shankar ^f   De Leon, Mony J ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d UNIVERSITY OF FLORENCE   (Italy)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Early detection; PET imaging; Presymptomatic

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BASAL GANGLION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; EDUCATION; FAMILY HISTORY; FATHER; FEMALE; FRONTAL CORTEX; HUMAN; LATE ONSET ALZHEIMER DISEASE; MALE; MOTHER; OCCIPITAL CORTEX; PARENT; PARIETAL LOBE; PATHOLOGY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TEMPORAL CORTEX; THALAMUS;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; BENZOTHIAZOLES; BRAIN; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 77950546575     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914141107     Document Type: Article

References (40)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356.
2. Farrer LA, et al.; APOE and Alzheimer Disease Meta Analysis Consortium (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 278:1349-1356.
3. Green RC, et al.; MIRAGE Study Group (2002) Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 287:329-336.
4. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239-259.
5. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45:358-368.
6. Klunk WE, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319. (Pubitemid 38269583)
7. 11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603-1606.
8. Pike KE, et al. (2007) Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130:2837-2844.
9. 11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67:446-452.
10. Mosconi L, et al. (2007) Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 48:19067-19072.
11. Mosconi L, et al. (2009) Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer's. Neurology 72:513-520.
12. Honea RA, Swerdlow RH, Vidoni E, Goodwin J, Burns JM (2010) Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 74:113-120.
13. Rowe CC, et al. (2007) Imaging {beta}-amyloid burden in aging and dementia. Neurology 68:1718-1725.
14. 11C]PIB uptake in Alzheimer disease. Neurology 67:1575-1580.
15. Li Y, et al. (2008) Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35:2169-2181.
16. Forsberg A, et al. (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456-1465.
17. 11C-PIB PET study. Neurology, in press.
18. Wolk DA, et al. (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65:557-568.
19. Reiman EM, et al. (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106:6820-6825.
20. Klunk WE, et al. (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27:6174-6184.
21. Remes AM, et al. (2008) Carbon 11-labeled Pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 65:540-544.
22. Johnson SC, et al. (2006) The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci 26:6069-6076.
23. de Leon MJ, et al. (2001) Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 98:10966-10971.
24. Jack CR, Jr, et al. (2005) Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 65:1227-1231.
25. Mosconi L, et al. (2008) Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 29:676-692.
26. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787-795. (Pubitemid 44622683)
27. Green KN, LaFerla FM (2008) Linking calcium to Abeta and Alzheimer's disease. Neuron 59:190-194.
28. Edland SD, et al. (1996) Increased risk of dementia in mothers of Alzheimer's disease cases: Evidence for maternal inheritance. Neurology 47:254-256.
29. Ehrenkrantz D, et al. (1999) Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease. Am J Med Genet 88:378-382. (Pubitemid 29372251)
30. Gómez-Tortosa E, et al. (2007) Variability of age at onset in siblings with familial Alzheimer disease. Arch Neurol 64:1743-1748. (Pubitemid 350254936)
31. Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M (2005) Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry 62:565-573. (Pubitemid 40628886)
32. Debette S, et al. (2009) Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology 73:2071-2078.
33. Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ (1994) A validation study of the Dementia Questionnaire. Arch Neurol 51:901-906.
34. Mormino EC, et al.; Alzheimer's Disease Neuroimaging Initiative (2009) Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132:1310-1323.
35. Johnson KA, et al. (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62:229-234. (Pubitemid 47525398)
36. Small GW, et al. (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652-2663.
37. Price JC, et al. (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25:1528-1547.
38. McKhann G, et al. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944.
39. Lopresti BJ, et al. (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 46:1959-1972.
40. Friston KJ, et al. (1995) Statistical parametric maps in functional imaging: A general linear approach. Hum Brain Mapp 2:189-210.